The Semipalatinsk Center for Nuclear Medicine and Oncology announced the release of a new 18F-PSMA-1007 radiopharmaceutical based on the fluorine-18 isotope. This was one of the most important achievements in the field of nuclear medicine, as the drug was produced for the first time in Kazakhstan and will help in the diagnosis of prostate cancer.
18F-PSMA-1007 - a radiopharmaceutical that accumulates in prostate tissues after being injected into the patient's body. This allows for high-precision detection of prostate cancer, metastases, or other oncological pathologies. Imaging is performed using PET / CT scanning, which significantly exceeds traditional radiodiagnostic methods in terms of accuracy and informativeness.
The entire process, from isotope synthesis to diagnostics, is carried out entirely on the basis of the Center for Nuclear Medicine and Oncology. At the initial stage, the fluorine-18 isotope is produced in a special cyclotron device. Then the isotope is sent to the synthesis laboratory, where chemists create the radiopharmaceutical. After that, the drug undergoes a thorough check in the quality control laboratory. Only then, taking into account the individual characteristics of the patient, the drug is packaged and delivered to the radionuclide diagnostics department.
After the drug is administered, the patient waits in a special ward until it accumulates in the body. Then a PET/CT scan is performed, the results of which are analyzed by oncologists. These data not only help to make an accurate diagnosis, but also determine further treatment tactics and monitor its effectiveness.
Professor Igor Znamensky noted that the master class includes attention to all stages of working with a radiopharmaceutical.
“We will comprehensively consider the process of administering the drug, the correct doses, the time required for accumulation, as well as patient preparation. We pay special attention to the methodology for interpreting the results of a PET/CT study. Because this is a crucial moment in determining the treatment strategy,” said the qualified specialist.
18F-PSMA-1007 was the third radiopharmaceutical whose full production cycle has been mastered at the center. This is an important step in the development of nuclear medicine in the country, which will not only expand diagnostic capabilities, but also improve the quality of cancer treatment. The new drug opens up opportunities for more effective treatment of prostate cancer and can become an important tool in the fight against oncology in Kazakhstan.

Source : https://www.gov.kz/memleket/entities/abay/press/news/details/933543